Cargando…
Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway
Hepatocellular carcinoma (HCC) is one of the most common cancers with an insidious onset, strong invasiveness, insensitivity to chemotherapy, and poor prognosis, thus makes clinical treatment challenging. The mechanisms require further elucidation for developing novel therapies and targeting drug re...
Autores principales: | Liu, Yun, Zhuang, Hao, Cao, Fang, Li, Jie, Guo, Yan, Zhang, Jun, Zhao, Qiang, Liu, Yuanyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961052/ https://www.ncbi.nlm.nih.gov/pubmed/33723262 http://dx.doi.org/10.1038/s41419-021-03560-8 |
Ejemplares similares
-
DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with β‐catenin to promote its ubiquitin degradation pathway
por: Li, Bo, et al.
Publicado: (2022) -
Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis
por: Liu, Yun, et al.
Publicado: (2023) -
Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma
por: Lin, Xian, et al.
Publicado: (2020) -
Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma
por: Deng, Ling, et al.
Publicado: (2019) -
Sarcomatoid hepatocellular carcinoma (SHC): a case report
por: Yu, Yingying, et al.
Publicado: (2017)